Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
March 06 2024 - 8:00AM
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage
biotechnology company pioneering the development of a novel class
of oncolytic immunotherapies, today announced presentations at the
upcoming American Association for Cancer Research (AACR) Annual
Meeting 2024 being held in San Diego, CA from April 5-10, 2024.
Details of the presentations are as follows:
Abstract Title: Initial results from an
open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid
organ transplant recipients with advanced cutaneous malignancies
(ARTACUS)Session Type: Oral
PresentationSession Title: Immunotherapy
Session Date and Time: Sunday, April 7, 2024 at
1:00 pm EDTAbstract Number: 9269
Abstract Title: Enhanced CD8+T-cell
infiltration, PD-L1 expression, and T-cell repertoire expansion in
patients with metastatic uveal melanoma responding to treatment
with RP2 alone or in combination with nivolumabSession
Type: Poster PresentationSession Title:
Immunomodulatory Interventions and MechanismsSession Date
and Time: Monday, April 8, 2024 at 9:00 am
EDTAbstract Number: 2467
About Replimune Replimune Group, Inc.,
headquartered in Woburn, MA, was founded in 2015 with the mission
to transform cancer treatment by pioneering the development of a
novel portfolio of oncolytic immunotherapies. Replimune’s
proprietary RPx platform is based on a potent HSV-1 backbone
intended to maximize immunogenic cell death and the induction of a
systemic anti-tumor immune response. The RPx platform is designed
to have a unique dual local and systemic activity consisting of
direct selective virus-mediated killing of the tumor resulting in
the release of tumor derived antigens and altering of the tumor
microenvironment to ignite a strong and durable systemic response.
The RPx product candidates are expected to be synergistic with most
established and experimental cancer treatment modalities, leading
to the versatility to be developed alone or combined with a variety
of other treatment options. For more information, please visit
www.replimune.com.
Investor Inquiries Chris BrinzeyICR
Westwicke339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Apr 2024 to May 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From May 2023 to May 2024